Will Ashworth

Will Ashworth

Expertise: Public and private companies, Portfolio construction

About Will:
Will Ashworth has written about investments full-time since 2008. He loves investing and is passionate about helping others put their money to work. He particularly enjoys creating model portfolios that stand the test of time.

Publications where he’s appeared include InvestorPlace, The Motley Fool Canada, Investopedia, Kiplinger, and several others in both the U.S. and Canada. He lives in Halifax, Nova Scotia.

You can follow Will on LinkedIn. 

Recent Articles

Vinco Ventures Doesn’t Look Any Better After This M&A Announcement

Vinco Ventures made a big acquisition causing BBIG stock to jump almost 20%. However, the rally was short-lived. Here’s why that’s the case. 

Aterian Talks a Good Game But It Isn’t Worth $14

The five analysts covering Aterian give ATER stock a median target price of $14. I’m not sure what they see in the consumer products company. 

Is Alibaba the Biggest Disappointment of the Class of 2014?

Alibaba’s been a public company for seven years. Yet BABA stock has barely doubled. Is it the biggest disappointment of the class of 2014? 

Buy Dutch Bros Stock as It Keeps Up the Burning-Hot Pace

Dutch Bros has been public for a month and yet BROS stock has almost doubled in this time. Can it keep up this blistering pace? 

10 Stocks to Buy for Their Billion-Dollar Buybacks

Consider these stocks to buy as their companies repurchase shares in the midst of the S&P 500's near-record-shattering quarterly buybacks.

Even an Oil and Gas Hater Knows Camber Energy Is Off Limits

Even with the rise of oil prices, Camber Energy ought to be permanently off-limits to oil and gas investors. Stay away from CEI stock.

SmileDirectClub is Headed for Penny Stock Territory

SDC stock might interest the Reddit crowd, but for most retail investors, SmileDirectClub is something to steer clear of.

Palantir Technologies Is Worth Getting Into Now, Though Another Dip Is Possible

Palantir Technologies reported strong Q2 results in mid-August.. Yet PLTR stock has fallen below where it was trading. Time to buy?  

Latest Bad News Suggests Novavax Stock Might Be Cursed

Merck’s experimental oral Covid-19 antiviral drug is not good news for Novavax or NVAX stock. It might be time to reconsider your bet.  

ContextLogic Stock Dips Deceive Investors as Shares Remain Expensive

ContextLogic lost 28% of its value in the past month. While WISH stock trades near $5, well off its February 52-week high, do not buy on the dips.